BillionToOne is a molecular diagnostics company whose proprietary Quantitative Counting Templates (QCT) platform measures DNA at the single-molecule level. Its UNITY Complete non-invasive prenatal test assesses fetal risk for aneuploidies, recessive conditions and antigens from a maternal blood draw. In oncology, Northstar Select and Northstar Response provide liquid-biopsy tools for therapy selection and treatment-response monitoring. The company serves clinicians and patients seeking highly sensitive blood-based genetic and cancer testing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 59 | — | -4 | — |
| Q2 2025 | 66.6 | — | -0.3 | — |
| Q3 2025 | 83.5 | — | 1.5 | — |
| Q4 2025 | 96 | — | 2.5 | — |
| Q1 2026 | 108.4 | 83.8% | 18 | — |
| Q2 2026 | 109.5 | 64.4% | 8.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: GDS Holdings Limited (GDS), Golar LNG Limited (GLNG), Atour Lifestyle Holdings Limited (ATAT), Colliers International Group Inc. (CIGI), Travere Therapeutics, Inc. (TVTX), VSE Corporation (VSEC)